Home Microbiology Bacterial chemical Amikacin disulfate

research use only

Amikacin disulfate Bacterial chemical

Cat.No.S3065

Amikacin sulfate (BB-K8) binds to 16S rRNA (bacterial 30S ribosome), causing misreading of mRNA and supressing proteins synthesis.
Amikacin disulfate Bacterial chemical Chemical Structure

Chemical Structure

Molecular Weight: 781.76

Jump to

Quality Control

Batch: S306501 Water]10 mg/mL]false]DMSO]Insoluble]false]Ethanol]Insoluble]false Purity: 99.68%
99.68

Solubility

In vitro
Batch:

Water : 10 mg/mL

DMSO : Insoluble
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Ethanol : Insoluble

Molarity Calculator

Mass Concentration Volume Molecular Weight
Dilution Calculator Molecular Weight Calculator

In vivo
Batch:

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg
g
μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO
%
% Tween 80
% ddH2O
% DMSO
+
%

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight 781.76 Formula

C22H43N5O13.2H2SO4

 Storage (From the date of receipt)
CAS No. 39831-55-5 Download SDF Storage of Stock Solutions

Synonyms BB-K8 Smiles C1C(C(C(C(C1NC(=O)C(CCN)O)OC2C(C(C(C(O2)CO)O)N)O)O)OC3C(C(C(C(O3)CN)O)O)O)N.OS(=O)(=O)O.OS(=O)(=O)O

Mechanism of Action

Targets/IC50/Ki
16S rRNA
In vitro
Amikacin sulfate has high affinities for 16S rRNA of the bacterial 30S ribosome, causing misreading of mRNA and leaving the bacterium unable to synthesize proteins vital to its growth. Amikacin is active in vitro against Pseudomonas species, Escherichia coli, Proteus species (indole-positive and indole-negative), Providencia species, Klebsiella-Enterobacter-Serratia species, Acinetobacter (formerly Mima-Herellea) species, and Citrobacter freundii. In vitro studies have shown that amikacin sulfate combined with a beta-lactam antibiotic acts synergistically against many clinically significant Gram-negative organisms. In vitro studies have shown that amikacin sulfate combined with beta-lactam antimicrobial agents including moxalactam or piperacillin acts synergistically against many clinically significant Gram-negative organisms.
In vivo
Amikacin (80 mg/kg i.v.) significantly reduced pseudomonal densities within aortic vegetations compared to controls in the experimental rabbit endocarditis model. In addition, amikacin given once daily is still more effective than the twice-daily regimen. Amikacin given alone at a dose of 50 mg/kg, in one, two, or three divided doses, showed remarkable activity in model of Mycobacterium avium complex infections in beige mice. Addition of clofazimine increased the activity significantly.
References
  • [4] http://www.ncbi.nlm.nih.gov/pubmed?term=4462458
  • [5] https://pubmed.ncbi.nlm.nih.gov/22339194/
  • [6] http://www.ncbi.nlm.nih.gov/pubmed?term=6792982
  • [7] http://www.ncbi.nlm.nih.gov/pubmed?term=9087497
  • [8] https://pubmed.ncbi.nlm.nih.gov/2848444/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT05555303 Recruiting
Tuberculosis Multidrug-Resistant
Rwanda Biomedical Centre|Institute of Tropical Medicine|World Health Organization
 March 1 2023 Phase 2
NCT05689450 Completed
Febrile Neutropenia (FN)
University Hospital Basel Switzerland
 December 21 2022 --
NCT05593601 Recruiting
Colonization Asymptomatic
Mahidol University
 November 24 2022 Phase 4
NCT05511129 Active not recruiting
COVID-19|Nosocomial Infection
Fondation Hôpital Saint-Joseph
 May 12 2022 --
NCT04239326 Completed
Tuberculosis Multidrug-Resistant
Foundation for Innovative New Diagnostics Switzerland
 April 16 2021 --

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.